ArticleVaccine2026
Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Tree-based scan statistics are used to study the safety of specific drugs or vaccines with respect to a broad range of health outcomes. But instead of choosing an exposure of interest and scanning patients' post-exposure outcome data, one can choose an outcome of interest and scan case-patients' pre-diagnosis exposures to vaccines, checking for potential associations. We used tree-based scan statistics, a new hierarchical structure of vaccines, and a self-controlled risk interval design to detect possible associations between vaccines and Guillain-Barré syndrome (GBS) in adults in the U.S. Vaccine Safety Datalink in 2017-2023. Incident GBS cases were identified with ICD-10-CM code G61.0. We assessed all vaccines administered in the 84 days prior to the incident GBS code, using a vaccine "tree" containing 99 CVX codes organized into 7 branches and 5 levels. We conducted both fixed and varying risk-window analyses. P ≤ 0.05 signaled a possible association. There were 2584 incident GBS cases; 40% were ≥ 65 years old. Only 25% had any vaccination code in the preceding 0-84 days. Using a Bernoulli tree-based scan statistic and risk and control windows of Days 1-21 and 43-84 before diagnosis, respectively, statistical signals were detected for influenza vaccines; Ad26.COV2·S (Janssen) COVID-19 vaccine; AS01-adjuvanted vaccines, including recombinant zoster; pneumococcal vaccines, including conjugate; and tetanus-diphtheria-acellular pertussis vaccine. Varying risk-window analysis found signals for influenza and Janssen COVID-19 vaccines. Attributable risk point estimates for these vaccines were in general agreement with other studies. All the vaccine groups that signaled, or their components, have had GBS signals in prior work. Conversely, there are no vaccines with a previously known association with GBS for which no signal was found. Tree-based data-mining holds promise for studying other outcomes suspected of association with vaccination, if case-finding algorithms are relatively specific, and allows detection of effects common to groups of related vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.